TECHNOLOGY TRANSFER COMMUNITY NEWSLETTER



July 2020

Rockledge II

Rockledge II Here We Come

Karen Rogers, OTT



While OTT staff will miss the quaint pink conference rooms and outdated conference equipment at 6011 Executive Boulevard, most are looking forward to moving to Rockledge II in October. Our newly renovated office space will have a 30-person conference room with the most up-to-date equipment. Furnishings and finishes throughout the office have been selected with care and reflect a modern approach. This new facility will also have robust security, cafeteria, exercise facility and a conference center.



Of course, physical return to the workplace whether it be 6011 Executive Boulevard or Rockledge II at 6701 Rockledge Drive, Floor 7, will depend on NIH guidance related to COVID-19. We don't anticipate a significant disruption in service provided by OTT but wanted to give the Technology Transfer Community notice of our upcoming move. We look forward to hosting meetings and training in our new office.



In This Issue

Do You Need Help Processing New Licenses?

Karen Rogers, OTT

The New License Processing and Systems Training was well received recently. We had about 70 staff attending or watching through WebEx for almost the entire 2 hours! A big thanks to Richard Rodriguez, Surekha Vathyam and Amber Rush for pulling together a very informative demonstration. This is the link in OTT SharePoint to the actual recording of the presentation and the "how to" guides and handouts we reviewed.

Everyone in the community should be able to access this page, but if you have any problems, please submit an IT Service Desk Ticket and select "Office of Technology Transfer" to submit a Help Desk Ticket.

They're All Fans of Dr. Fauci Now!

Richelle Holnick, OTT

Bobbleheads, t-shirts, stickers, and even facemasks are all items available to be bought online bearing pictures of Dr. Anthony Fauci or referencing him. With the coronavirus outbreak, Dr. Fauci became a household name and beloved by many. There are social media pages dedicated to discussing him, both his work and people's appreciation of him. During this pandemic, Dr. Fauci has gained a legion of fans, from actors and comedians to regular people looking to him for guidance, who often refer to themselves as the Fauci Gang.

Watch me bobble!

Many people have started producing Dr. Fauci paraphernalia. There are many Etsy and Redbubble independent sellers creating every possible item you could think of - stickers, pins, greeting cards, t-shirts - the list goes on and on. A few of these larger sellers created this merchandise with the intent to donate a portion of their profits. The National Bobblehead Hall of Fame and Museum started selling Dr. Fauci bobbleheads (pictured above) in April with the intent of donating $5 per sale. His bobblehead became their best seller in less than a week. They have donated over $100,000 to the American Hospital Association's "100 Million Mask Challenge" from the sales.

Celebrities also got involved in promoting these campaigns and praising Dr. Fauci. Orlando Bloom and Katy Perry posted on Instagram in 'Fauci Gang' hoodies sold by Pizzaslime, who donated money from their now sold-out hoodies to the CDC's Foundation Emergency Response Fund. Another celebrity that used their platform was Julia Roberts, who hosted the first #PassTheMic campaign event by having Dr. Fauci discuss the facts, science, and data surrounding the coronavirus pandemic. Saturday Night Live showed their appreciation of Dr. Fauci by having Brad Pitt portray him on the April 25th cold open. Pitt ended his skit by saying "to the real Dr. Fauci, thank you for your calm, your clarity, in this unnerving time."

Click to watch video clip of Brad Pitt appearing as Dr. Fauci in Saturday Night Live

Fauci Fans

It comes as no surprise that the nation's attention is on Dr. Fauci, or that his items are best sellers. Since the creation of the Coronavirus Task Force, people have been voicing their appreciation of Dr. Fauci for his guidance. "His comforting and intelligent demeanor has helped to lessen our national anxiety. He speaks truth to power, a strength few have at this time," stated Sandra Martin in her petition to People Magazine to make Dr. Fauci this year's Sexiest Man Alive. While the general public is now becoming large fans of Dr. Fauci, this is not the first time he has been at the forefront of confronting viral diseases in the US. His guidance and work helped the US through the HIV/AIDs crisis, SARS, Ebola, and the Swine Flu, among many others throughout his career as the director of NIAID. Dr. Fauci is a distinguished scientist and inventor with a laundry list of accomplishments, including 17 inventions, many awards, over 30 honorary doctorate degrees, a Presidential Medal of Freedom, and now, a well-deserved fan base.

Federal Labratory Consortium

Ami Gadhia, NCATS

FLC

The Federal Laboratory Consortium (FLC) includes over 300 federal laboratories. The FLC is governed by its Executive Board which is composed of nationally elected positions—FLC Chair, Vice-Chair, Finance Officer, Recording Secretary, the Host Agency Representative, six Regional Coordinators, and six Members-at-Large. The chairs of standing committees are appointed by the Executive Board. Collectively, the FLC Executive Board determines organizational policy and direction, as well as establishes the annual budget.

The Regional Coordinators (RCs) and Deputy Regional Coordinators (DRCs) carry out the activities of the region. Each Consortium member laboratory is a member of the region in which it is located. The FLC is organized into six regional subdivisions to best serve its geographically diverse and large membership. These subdivisions include: Far West, Midwest, Mid-Atlantic, Mid-Continent, Northeast, and Southeast. NIH is largely in the Mid-Atlantic Region. The Mid-Atlantic regional meeting is often held in Rockville (near Shady Grove). It's a terrific opportunity to share best practices, and learn from colleagues at different ICs and agencies.

FLC and the Association of University of Technology Managers (AUTM) entered into a cooperative agreement in November 2019, and therefore will work together to improve the impact from federal lab technology transfer. NIST made a 5-year award to AUTM on behalf of the FLC Executive Board to AUTM for the Enabling Federal Technology Transfer (EFTT) Program. There is no incumbent for this award, since it's a new mechanism for the FLC to engage with a partner.

The upcoming Annual Meeting will be on August 31- September 3 and will be digitally delivered at no cost to attendees. It's a great opportunity to learn and network with fellow federal lab colleagues.

We have a number of HHS colleagues involved in FLC. Below is a chart illustrating the current individuals holding official FLC positions;

FLC Member	Position
Karen Rogers	Agency (NIH) Representative
Juliana Cyril	Agency (CDC)) Representative
Alice Welch	Agency (FDA) Representative
Whitney Hastings	Awards Committee Chair
Ami Gadhia	FLC Member-at-Large

The results of the runoff election are in! Additional HHS colleagues will join the FLC Executive Board on October 1, 2020: Thomas Stackhouse, Member-at-Large; Vladimir Popov, Mid-Atlantic Regional Coordinator; Claudia Haywood, Mid-Atlantic Deputy Regional Coordinator. Congratulations to our colleagues, and many thanks to the TDCs who voted. The races were close. Other elected FLC Board Members include: Courtney Silverthorn, Finance Director (re-elected); John Bittman, Recording Secretary; Valerie Larkin, Member-at-Large; David Pronchick, Member-at-Large; Jenna Dix, Midwest Regional Coordinator (re-elected); Sabra Tomb, Midwest Deputy Regional Coordinator (re-elected); and David Nicholson, Far West Regional Coordinator.

Congratulations also to the 2020 FLC National Awards winners! NIH and CDC had a number of winners in various categories. The Impact Award and the Technology Transfer Innovation Award were added award categories this year.

It's time for you to make your nomination for the Mid-Atlantic Regional awards! Click here to make your nomination.

TTIPO Key Player in NIAID's COVID-19 Response

Jasmine Kalsi, NIAID

Scientists at the NIH initiated foundational work on SARS-CoV-2 long before it became a national crisis. To ensure that scientists can collaborate and create technical solutions, the institutes rely on vital efforts of often unrecognized Technology Transfer professionals. The Technology Transfer and Intellectual Property Office (TTIPO) is helping to make NIAID's all-important scientific advancements possible. Those working in the field understand that the TTIPO is the first line of defense, ensuring legal and policy compliance and securing the scientific workflow. Fig. 1 NIAID TTIPO COVID-19 Agreements by type as of 18 June 2020, shown to the right.



Credit: Jasmine Kalsi

As evident from previous epidemics and pandemics, the first step in combatting a new biological threat is to study it. For SARS-CoV-2, obtaining samples from the epicenter of the outbreak was instrumental to research. The TTIPO initiated communication and successfully coordinated with the Hong Kong Government, and used its Global Health Security Initiative (GSHI) contacts to secure samples from four other countries. The TTIPO worked with the Office of Global Affairs (OGA), the Office of the Assistant Secretary for Preparedness and Response (ASPR), Biomedical Advanced Research and Development Authority (BARDA) and the Department of State on ensuring that samples could be easily shared globally and was instrumental in shaping the World Health Organization (WHO) guidance regarding international cooperation. In fact, a graph (Fig. 1) of COVID-19 related efforts by TTIPO reflects the significance of materials transfer in the fight to combat COVID-19. To date out of 401 agreements, 232 have been request for transfer of materials.

A significant and essential component to national efforts on combatting SARS-CoV-2 is the participation of the private sector. From discovery to clinical phase, the NIAID TTIPO has initiated and completed various agreements to facilitate industry partnership. The office is responsible for supporting the negotiation of Clinical Trial Agreements (CTAs) that have enabled collaborations with Gilead and Moderna, the two big names in SARS-CoV-2 private effort. The Gilead CTA allows for clinical evaluation of Remdesivir as a therapeutic at 68 sites around the world.

The Moderna CTA explores a mRNA-based vaccine for SARS-CoV-2, enabling the company to become one of the first in the world to conduct first-in-human trials of a COVID-19 vaccine. The BARDA of HHS awarded Moderna a contract to accelerate vaccine development

through licensure and manufacturing scale-up (https://www.medicalcountermeasures.gov/newsroom/2020/moderna-vaccine/), and this project has received a fast-track designation from FDA. Notable successfully negotiated agreements for therapeutics development include testing of Remdesivir in a SARS-CoV-2 challenge in NHPs, the identification of therapeutic novel antibodies against SARS-CoV-2, and characterization and development of fully human monoclonal antibodies (hmAbs) against coronaviruses, including SARS-CoV-2. Since the beginning of 2020, the NIAID TTIPO has helped to set in motion 14 clinical trials.



Credit: Haiqing Li

Utilizing the powerful congressionally granted authority of licensing federal inventions, the TTIPO has successfully incentivized industry partners to develop new vaccines, therapeutics, and point of care diagnostics. As of 18 June 2020, the NIAID TTIPO has granted 16 non-exclusive licenses related to COVID-19.
Fig. 2 NIAID TTIPO COVID-19 related executed Agreements as of 18 June 2020.

Another impressive achievement advanced by the NIAID TTIPO in response SARS-CoV-2 is the partnership to accelerate development of 3D-printed protective gear. Through a strategic interagency Memorandum of Understanding (MOU), the FDA, VA and HHS, represented by NIAID, are working to maximize access to NIH's 3D Print Exchange and streamline the testing, safety and effectiveness of proposed solutions. In less than a week, this united front led to the testing of two face shield prototypes and a face mask. Yet another instance of life-saving technology enabled by TTIPO.
In response to the COVID-19 outbreak, the TTIPO has put in place close to 400 agreements. These include notoriously complex and often time-consuming agreements such CRADAs and CTAs, negotiated at a remarkable rate, as reflected in figure 2 (Fig 2.). The tireless work of NIAID's scientists is made possible by the tireless work and dedication of their TTIPO support team. The Technology Transfer and Patent Specialists (TTPS) of the TTIPO continue to work hard for our scientists, Dr. Fauci, the NIH and the nation, driven by the same passion and drive to make a difference.

National Institute of Allergy and Infectious Diseases

NIH and the Center for Advancing Innovation Launch the Innovate Children's Health Challenge

Michele L. Newton, NCI

The Center for Advancing Innovation (CAI), in partnership with the NIH, recently kicked off the Innovate Children's Health Challenge. NCI along with NCATS, NHGRI, NHLBI, NIAID and NIDCR each have inventions featured in the new startup Challenge (see featured inventions). NCI Technology Transfer Center (TTC) Director, Dr. Tom Stackhouse and TTC Associate Director Richard Rodriguez worked closely with CAI to establish the latest challenge and coordinate involvement by NIH ICs. Through CAI, the Challenge is also supported by Resonance Philanthropies, a donor-advised fund of the Silicon Valley Community Foundation.

"As with CAI's prior challenges, teams will advance promising de-risked inventions selected with rigorous due diligence by potential investors and industry experts," explains the Challenge website. "Teams may also enter with their own commercially viable inventions. CAI invites anyone to submit an idea with the potential to improve children's health around the world. An expert judging panel will select a total of 15 winners from the pool of teams, advancing promising inventions, and individuals with the best ideas."

There are three ways to participate in the Innovate Children's Health Challenge:

1. Entrepreneurial-minded people — individually or in teams — may compete to commercialize vetted inventions

2. Existing startups may enter the challenge with other children's health-related inventions, including their own and/or others to which they have access

3. Participants may submit ideas that they believe will improve children's health. CAI will help ideators create a business model to advance their solutions

Starting with the Breast Cancer Startup Challenge in 2014, TTC worked with CAI to establish several startup challenges — a strategic initiative to encourage licensing and collaborative development of NCI technologies, and encourage the formation of startups around those technologies. After the Breast Cancer Startup Challenge, the scope of the Neuro and Nano Startup Challenges expanded to include other NIH ICs and inventions from other organizations. A June 9th press release issued by CAI kicked off the Challenge.

By the last week of June, 32 teams enrolled to compete for a chance to license the technologies. At the current pace, it's estimated that around 100 companies may end up competing for a chance to license a technology in (which will include other technologies in addition to the NIH technologies) the Challenge. Winners of the Challenge will have to apply for a license and go through the regular NIH license process to obtain a license.

Teams interested in applying can enter here. There is also an opportunity to participate by recruiting, advising, mentoring or judging teams: Learn more

This Day In Tech Transfer History

Diamond v. Chakrabarti

Barry Buchbinder, NIAID

June 16th marked the 40th anniversary of when the Supreme Court issued its ruling on *Diamond v. Chakrabarti* after having been argued on March 17, 1980. In this ruling the Supreme Court held that "A live, human-made micro-organism is patentable subject matter under 101. Respondent's micro-organism constitutes a 'manufacture' or 'composition of matter' within that statute". It was a landmark decision surrounding the genetically engineered "hydrocarbon-degrading Pseudomonas") that paved the way for claiming patent rights to genetically modified organisms (GMOs) and opened further opportunities for technology transfer and the biotechnology industry. US Patent 4,259,444 then issued on March 31, 1981. Sadly, Dr. Chakrabarty passed away on July 10, 2020.

Pictured: Dr. Chakrabarty

Enterprise Technology System Updates

Tim Leahy, OTT

The NIH Technology Transfer community started to develop the Enterprise Technology Transfer (ETT) System after the need for a robust, centralized IT platform to support technology transfer was identified. The ETT System is being developed in partnership between the Office of Technology Transfer and the technology transfer offices within the ICs. The development and ongoing improvement of this system is being guided by the Technology Transfer User Group (TTUG), which is made up of senior stakeholders from across the entire NIH Technology Transfer community.

The OTT has taken a long-term approach to IT management to ensure the longevity of the ETT System. After identifying the full scope of business processes used by the NIH Technology Transfer Community, OTT found the points at which applications can best be leveraged to support these processes and has planned for the implementation and tailored configuration of Inteum's "Minuet" software, which has been selected as the commercial off-the-shelf (COTS) product for the future ETT system.

The ETT team has continued to progress towards the launch of the ETT System. While approaching the conclusion of the configuration requirements sessions, the ETT team shifted their focus to preparing the TTUG for testing and training. Progress also continued on the data migration tasks, implementation of security controls, and staging environment set-up. Stakeholders from all of the ICs have been actively participating in many TTUG and Governance Board meetings to gather project requirements and agree on priorities and goals for the new system.

Milestones

•Continued gap analysis and ETT implementation planning with Inteum and NIH Tech Transfer stakeholders

•Facilitated TTUG (Technology Transfer User Group) meetings to document business requirements for configuration of the Minuet system interface

•Worked with Inteum to define/analyze financial management features Inteum

•Developed use cases and test cases for ETT system core business functions

•Finalized the detailed functional requirements necessary to support NIH technology transfer community business processes

•Created, reviewed, and verified the ETT user training approach and schedule with TTUG and ETT Governance Board

•Continued work on prototype for new LFP website, after securing API from Inteum

•Continued practice migrations and validation of legacy system data sets, as well as refinement of the data migration reference document to facilitate the migration of data into the

ETT system

•Updated information on law firm invoice processing for the new Patent Legal Services (PLS) contract, and drafted initial workflow with input from IC personnel

•Continued preparation of security documentation for the ETT Authority to Operate

•Began the process of setting up users in the STAGE environment

Upcoming Quarter

In the upcoming quarter, overview and module training will be scheduled to allow users to gain familiarity with the system and become comfortable using the new application to perform common tasks. The team has successfully integrated Minuet with the NIH Single Sign-On, which will allow users to log in to the system using their NIH credentials.

We will be continuing to provide regular updates on the status of the implementation to the members of the TTUG so they can relay the information to their respective organizations.

As progress is made on the new ETT system, we thought it would be nice for users to get a preview of how the user dashboard will appear. The data shown on the dashboard will be customized to each user; however, it will show these general fields. Included below are two different views from the dashboard.

Pictured to the left is a sample design of how the user dashboard will appear when accessing the system.

Pictured to the right is the agreements module. It is an example of the different views available that have similar structure with different fields.

Best Browsers for Navigating SharePoint

Terry Goodell, Sapient

The easiest way to get the most of your SharePoint experience is to use Internet Explorer or Firefox to access the site. Browsers are constantly updating to provide improved user experience and stronger security. Unfortunately, some of these updates are not completely compatible with SharePoint 2016. As a result, we periodically have to revise our recommendations about which browsers to use. Using other popular browsers could produce errors on the page, or the pages and windows within the browser might come up skewed or compressed.

Browser Recommendation (as of June 2020)

*Please make sure you have the latest version of the browsers for security

Browsers Recommended	Browsers Not Recommended
Internet Explorer	Microsoft Edge
Firefox	Chrome
	Safari

Please note that these recommendations might change for newer releases, at which time we will update these guidelines.

NCI TTC Engages Potential Collaborators and Licensees at Digital BIO International Convention

Michele Newton, NCI

Digital BIO Convention

On June 8-12, representatives from NCI TTC's Invention Development and Marketing Unit (IDMU) participated in BIO Digital 2020. The BIO International Convention, typically one of the most widely attended biotechnology technology conferences in the world, was previously planned to be an in-person event in San Diego. However, like most events planned for 2020, it pivoted to a virtual offering. To that end, BIO was able to facilitate virtual one:one partnering – in 2019, the offering was noted as being one of the largest one:one partnering events in the world. This year, more than 7,000 participated from 64 countries across 28 time zones. IDMU Supervisor, Dr. Michael Salgaller, spoke with more than 40 companies to establish new partnering and licensing opportunities on behalf of NCI and the NIH IC's that TTC supports. The IDMU has already had several follow-up conversations with connections made through the virtual event.

In addition, Dr. Salgaller organized and hosted a panel presentation entitled, Many Happy Returns: Federal Labs as Commercialization Partners, Turning Public Support into Marketed Innovations that included perspectives from various federal labs and a federal industry partner. To learn more, view the video of the panel (please note: there is an issue with audio of an embedded video presented by Dr. Courtney Silverthorn):

Panelists in order of appearance:
Courtney Silverthorn, PhD - National Institute of Standards and Technology
Steve Ferguson - National Institutes of Health
Barry Datlof - Department of Defense
Richard Ward, PhD - AstraZeneca

NIH Librarian's T2 Tip Of The Month -- Embase

Josh Duberman, NIH Library

This month's T2 tip from your NIH Library highlights Embase, often called the "underestimated secret weapon of literature researchers", and very useful for technology transfer-related projects. Embase covers pharmacological & biomedical literature, with more than 38 million records from more than 8,500 journals in 40 languages. It has a focus on key European-based clinical medicine studies as well as conferences, medical devices, biotechnology, drug side effects/ interactions, toxicology and health policy issues. Searchers can drill down to such relevant issues as market size, patents, and licences (British spelling.) To get started with Embase simply go to https://www.embase.com/ after logging into NIH VPN. For information on future training on Embase and other NIH Library resources, click here for the NIH Library class schedule, or sign up for the NIH Library email news at https://www.nihlibrary.nih.gov/library-email-news-signup

Tech Toon "Single Use"

Comic by Charlotte Kanzler, UW-Madison, Cellular and Molecular Biology Grad Student

Comings and Goings

Diptadip Dattaroy has a PhD in Environmental Health Sciences from the University of South Carolina. Before joining NCI TTC, Diptadip was a postdoctoral fellow at the NIDDK, where he studied the cellular mechanisms in Type 2 Diabetes. Diptadip was also a Technology Transfer Ambassador at the NCI and has taken several courses in Technology Transfer from the FAES Graduate School. He is eager to work in the business side of science and is passionate about assisting in the commercialization of new scientific innovations that impact the lives of others.

Steven Ferguson of OTT has been elected to the Board of Directors for NIH's Foundation for Advanced Education in the Sciences (FAES). At FAES he also continues to serve as Department Chair and Faculty for their "Advanced Studies in Technology Transfer Program". July also marks Steve's 30th anniversary of joining OTT and he is very relieved to be finally finished with his probationary period!

Richelle Holnick joined OTT in May 2020 from Publicis Sapient to provide full-time support for technology transfer marketing activities. As Marketing Coordinator, she will be playing an active role in developing new initiatives and content related to newsletters, web sites, annual reports and general digital content for NIH technology transfer. Richelle holds a degree in Business Administration with a marketing major along with a digital studies minor and previously worked in social media marketing for the Center for International Education at the University of Mary Washington.

Daniel Lee joined TTIPO in July, 2020 from the NCI Technology Transfer Center (TTC). Prior to this position, he worked for a private equity firm, law firms, and a technology accelerator, where he set up a patent and licensing strategy for precision medicine, drug discovery, microbiome, and piezoelectric data projects. Daniel has a bachelor's degree in computer engineering.

Michaela McCrary, Ph.D. joined NCI TTC in June 2020 as a CRTA fellow. Before joining TTC, Michaela pursued her Ph.D. in biomedical engineering at the University of Florida. Her work focused on developing novel biomaterial approaches for spinal cord injury repair and development of novel in vitro models of central nervous system trauma. During her graduate work, Michaela became interested in tech transfer after participating in multiple invention disclosures, patent applications, and agreements associated with her research.

Jenish Patel, formerly of NIAID TTIPO, has joined the Technology Transfer Program of the Department of Veterans Affairs (VA) Office of Research and Development in Washington, DC as a Technology Transfer Specialist. His new article with NIH colleagues regarding vaccine development by the Serum Institute of India is expected to be published later this year.

Surekha Vathyam, Ph.D. joined NIAID TTIPO as the Deputy Director in June, 2020. Previously, she was part of the leadership team at the NCI TTC overseeing technology transfer operations. Before joining the NCI, she was a Senior Licensing and Patenting Manager at the NIH OTT, where she evaluated, marketed, licensed and managed a wide range of NIH and FDA inventions and other intellectual property. Prior to her appointment at the NIH, she was a Patent Examiner at the USPTO in the Chemistry Technology Center. Her professional experience also includes service as Director of the Research & Development and Director of Manufacturing in a biotech company where she negotiated contracts and licenses, while developing medical diagnostics and therapeutics.

Lawrence Wu has left his position as a technology transfer specialist with the National Institute of Dental and Craniofacial Research (NIDCR). He has joined MIT's Technology Transfer Office, working with the Catalyst Fellows. Each year of this program is designed to bring researchers and practicing professionals in areas surrounding healthcare together to develop a biomedical research project. His great work here was appreciated and he will be remembered fondly. We wish Lawrence all the best.